Term
|
Definition
best for increasing HDL
(1) lowers TG synthesis
(2) decreased lipolysis in adipose tissue (decreased FFA)
(3) reduced hepatic clearance of HDL |
|
|
Term
|
Definition
Fibrate (1st); marked reduction in VLDL
(1) LPL synthesis (clearance of TG-rich lipoproteins)
(2) inhibition of apoC III expression (enhance VLDL clearance)
-GALLSTONES |
|
|
Term
|
Definition
| Fibrate; marked reduction in VLDL |
|
|
Term
|
Definition
| Fibrate; marked reduction in VLDL |
|
|
Term
|
Definition
| Fibrate; marked reduction in VLDL |
|
|
Term
|
Definition
| Fibrate; marked reduction in VLDL |
|
|
Term
|
Definition
Bile Acid Sequestrants (binds negatively charged bile acids)
-reduces LDL; slight increase in TG and HDL
-COMBO w/ statins |
|
|
Term
|
Definition
Bile Acid Sequestrants (binds negatively charged bile acids)
-reduces LDL; slight increase in TG and HDL
-COMBO w/ statins |
|
|
Term
|
Definition
Bile Acid Sequestrants (binds negatively charged bile acids)
-reduces LDL; slight increase in TG and HDL
-COMBO w/ statins |
|
|
Term
|
Definition
HMG-CoA reductase inhibitor (statins)
-1st one studied |
|
|
Term
|
Definition
HMG-CoA reductase inhibitor (statins)
-1st approved by FDA |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor (statins) |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor (statins) |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor (statins) |
|
|
Term
|
Definition
HMG-CoA reductase inhibitor (statins)
-longer t1/2 (lipitor) |
|
|
Term
|
Definition
HMG-CoA reductase inhibitor (statins)
-longer t1/2 (crestor) |
|
|
Term
|
Definition
inhibits enterocyte abs. of cholesterol in intestine
-new drug (best in combo w/ statins) |
|
|
Term
|
Definition
| weak diuretics, lower BP, improve symptoms of congestion |
|
|
Term
|
Definition
|
|
Term
| amiloride, spironolactone |
|
Definition
| potassium sparing diuretics (reduce K+ depletion) |
|
|
Term
|
Definition
| Central sympathetic drug, alpha 2 agonist (pregnancy) |
|
|
Term
|
Definition
| central sympathetic, alpha 2 agonist, used when traditional means to control BP fails |
|
|
Term
|
Definition
| adrenergic neuron blocking agent |
|
|
Term
|
Definition
| adrenergic neuron blocking agent |
|
|
Term
|
Definition
| adrenergic beta receptor blocker (non-selective) |
|
|
Term
|
Definition
| adrenergic beta receptor blocker (B1 selective) |
|
|
Term
|
Definition
| adrenergic beta receptor blocker (B1 selective) |
|
|
Term
|
Definition
adrenergic beta receptor blocker (non-selective)
-also alpha-1 blocker |
|
|
Term
|
Definition
| adrenergic beat receptor blocker (B1 selective) |
|
|
Term
| Adrenergic alpha receptor blockers |
|
Definition
| blocks alpha 1; given at bed to avoid orthostatic effect |
|
|
Term
|
Definition
direct vasodilator (use w/ beta-blocker)
-short t1/2; lupus-like syndrome
-NO release |
|
|
Term
|
Definition
direct vasodilator (use w/ beta-blocker)
-NO release
-avoid prolonged use in renal failure (CN build-up) |
|
|
Term
|
Definition
direct vasodilator (use w/ beta-blocker)
-hyperpolarize SM (opening K channels) |
|
|
Term
| Amilodipine (felodipine. isradipine) |
|
Definition
| Calcium channel blocker (vasoselective = dihydropyridines) |
|
|
Term
|
Definition
| Calcium channel blocker (vasoselective = dihydropyridines) |
|
|
Term
|
Definition
| Calcium channel blocker (nondihydropyridines) |
|
|
Term
|
Definition
| Calcium channel blockers (nondihydropyridines) |
|
|
Term
| (end w/ pril) captopril, enalapril, lisinopril, ramipril, quinapril, fosinopril |
|
Definition
|
|
Term
| (end in -sartan) losartan, irbesartan, valsartan, candesartan, olmesartan, telmisartan |
|
Definition
| Angiotensin receptor blocker |
|
|
